NASDAQ:CERSCerus Stock Price, Forecast & News

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CERS stock has increased by 46.8% and is now trading at $6.99.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cerus.

Cerus is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cerus.

Cerus Co. (NASDAQ:CERS) issued its quarterly earnings results on Tuesday, August, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The biotechnology company earned $21.50 million during the quarter, compared to the consensus estimate of $21.50 million. Cerus had a negative return on equity of 76.83% and a negative net margin of 83.78%.
View Cerus' earnings history.

Cerus updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $112.8 million.

4 brokerages have issued 12-month price objectives for Cerus' shares. Their forecasts range from $6.50 to $9.00. On average, they anticipate Cerus' share price to reach $7.63 in the next year. This suggests a possible upside of 9.1% from the stock's current price.
View analysts' price targets for Cerus.

News stories about CERS stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cerus earned a daily sentiment score of -1.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
View the latest news about Cerus.

Some companies that are related to Cerus include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), OraSure Technologies (OSUR), Meridian Bioscience (VIVO), Antares Pharma (ATRS) and Anika Therapeutics (ANIK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Opko Health (OPK), Immunomedics (IMMU), Advanced Micro Devices (AMD), Pfizer (PFE) and ACADIA Pharmaceuticals (ACAD).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus' stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.54%), Vanguard Group Inc. (5.31%), Paradigm Capital Management Inc. NY (0.92%), Peregrine Capital Management LLC (0.88%), Raymond James & Associates (0.73%) and Silvercrest Asset Management Group LLC (0.58%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman.
View institutional ownership trends for Cerus.

CERS stock was sold by a variety of institutional investors in the last quarter, including Pier Capital LLC, Silvercrest Asset Management Group LLC, Peregrine Capital Management LLC, FMR LLC, Paradigm Capital Management Inc. NY, Lesa Sroufe & Co, Bank of America Corp DE, and CFM Wealth Partners LLC. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

CERS stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., UBS Group AG, Marshall Wace North America L.P., EAM Investors LLC, Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Cubist Systematic Strategies LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $6.99.

Cerus has a market capitalization of $1.16 billion and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.

The official website for Cerus is www.cerus.com.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]